Feng Zhang's lab develops potential breakthrough in RNA editing delivery using 'ultracompact' versions of Cas13

Kyle Blankenship

As one of the pioneers behind CRISPR, the Broad Institute’s Feng Zhang has fashioned himself into a gene editing Renaissance man in recent years with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Feng Zhang's lab develops potential breakthrough in RNA editing delivery using 'ultracompact' versions of Cas13

Kyle Blankenship

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Applied Therapeutics' rare disease drug gets a CRL

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Feng Zhang's lab de­vel­ops po­ten­tial break­through in RNA edit­ing de­liv­ery us­ing 'ul­tra­com­pact' ver­sions of Cas13

Kyle Blankenship

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Feng Zhang's lab develops potential breakthrough in RNA editing delivery using 'ultracompact' versions of Cas13

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Applied Therapeutics' rare disease drug gets a CRL

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life